Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina News
Tailor Bio Receives £650K UK Biomedical Grant to Develop Predictive Diagnostic for Ovarian Cancer
The startup will work with Illumina and the University of Cambridge to develop a test that identifies which ovarian cancer patients won't respond to doxorubicin chemotherapy.
Imagia Canexia Health Garners CE-IVD Mark for Comprehensive Cancer Testing Platform
Having met the requirements for self-certification, the company is readying to deploy its Imagia Canexia Health Insights Platform to oncologists in Europe.
The program includes a new national infrastructure for diagnostics and a clinical trial, which have identified targeted treatments for dozens of patients.
Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit
Guardant claimed that a patent lawsuit filed against it by Illumina in March was filed in an inappropriate district court and is a “brazen attempt” to stifle competition.
Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection
The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib).